With a total investment of 730 million yuan, a therapeutic monoclonal antibody pilot plant was built which offers a scale of up to 2000 L for the production of monoclonal antibodies for clinical tests and will be further scaled up to 80.000L, enough to produce 3 tons of monoclonal antibody protein (anti tumor) per year. The plant is located in Fujian’s Sanming Hi-Tech Zone.
China Bio news release, August 29, 2015
Fuzhou CreMab Pharmaceutical Co. and Fujian-based partners build independent manufacturing base for therapeutic antibodies